Dataset Information

Proteomic Analysis of USP17LA-Interacting Proteins in 293T Cells

ABSTRACT: To explore the interaction network of USP17LA, we overexpressed it in HEK293T cells and performed IP-MS to identify associated proteins and potential targets.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Culture

SUBMITTER: huiling Zhang

LAB HEAD: Duanwu Zhang

PROVIDER: PXD065847 | Pride | 2025-11-17

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

Items per page:

1 - 4 of 4

Publications

The deubiquitinase USP17LA negatively regulates T-cell activation and attenuates anti-tumor immunity.

Zhang Huiling H Guo Zhihan Z Wei Gaigai G Yi Jingjing J Wang Zixi Z Zhang Yuqi Y Zhao Haiping H Ren Tingrong T Wang Yihan Y Kuang Jiating J Sheng Zhaoying Z Zhang Duanwu D

EMBO reports 20250929 21

T-cell activation is essential for effective immune responses, yet its precise regulatory mechanisms remain incompletely understood. In this study, we show that the deubiquitinases of the Ubiquitin-Specific Peptidase 17-like (USP17L) family are significantly upregulated following T-cell stimulation. Using CRISPR-mediated gene knockout mice, we demonstrate that USP17LA, but not USP17LB, acts as a negative regulator of T-cell activation. Loss of Usp17la leads to increased production of pro-inflamm ...[more]

PMID: 41023441

Similar Datasets

Project description:Drugs targeting mutant oncogenes are effective, even though resistance rapidly develops. This complex picture includes acquired intrinsic tumor and tumor microenvironmental -mediated mechanisms. Here we showed that melanoma cells resistant to BRAF inhibitors (BRAFi) overexpressed the rate limiting enzymes involved in nicotinamide (NAM) metabolism nicotinamide phosphoribosyltransferase (NAMPT) and nicotinamide N-methyltransferase (NNMT). Importantly, NAMPT and NNMT are released by these cells, both in the free-form or loaded in extracellular vesicles (EVs). NAMPT is emerging as mediator of BRAFi resistance in melanoma, but to date mainly associated with its role as main NAD-biosynthetic enzyme. It had been previously identified as soluble factor, but never in EVs released from melanoma cells, which highlights an impact on the tumor microenvironment (TME). NNMT was revealed increased in melanoma compared to benign nevi, however we showed for the first time its overexpression in resistant cells at intracellular and extracellular levels (present in secretome and in EVs). NNMT increased in BRAF-mutated patients linking its expression with the BRAF oncogenic signaling and correlates positively with pro-inflammatory signaling, immune cell migration and chemokine-mediated signaling pathways opening to a future deeper exploration of its functional role. Lastly, we proposed a tetrameric NNMT:TLR4 binding model offering a plausible structural and mechanistic basis for their association. Overall, the identification of NAMPT and, surprisingly also NNMT, included in EVs and abundantly released from resistant melanoma cells supports the impact of these moonlighting proteins involved in nicotinamide metabolism as mediators of BRAF/MEK inhibitors resistance with tumor intrinsic and potentially tumor microenvironment-mediated mechanisms. Interfering with nicotinamide metabolism could be a valid strategy to counteract drug resistance acting on the multifactorial tumor-host interactions.

			Action	DRS
	20240613_EV.raw	Raw
	20240613_EV.xlsx	Xlsx
	20240613_USP17LA.raw	Raw
	20240613_USP17LA.xlsx	Xlsx